In light of these results, development of more potent and stable second-generation agonists of LRH-1 that can be administered orally (BL001 having a short half-life via this route), rather than daily intraperitoneal injections, may prove to be a feasible therapeutic alternative and/or complement to insulin treatment for T1DM patients. This evidence concerns the gene INS and type 1 diabetes mellitus.